Pfizer Inc. (PFE)
The price, the headline numbers and the latest news, in one place.
Pfizer Inc. (PFE) Stock Price, Analysis & Data
| Bid | 28.48 |
| Market Cap | 162.84B |
| Revenue (ttm) | 63.7B |
| Net Income (ttm) | 4.34B |
| 0.28 | |
| 0.76 | |
| 37.59 | |
| 9.87 | |
| P/B (ttm) | 1.91 |
| P/S (ttm) | 2.56 |
| Earnings Date | Nov 3, 2026 |
| Ask | 28.55 |
| Volume | 31,840,109 |
| Avg. Volume (20D) | 42,531,167 |
| Open | 27.91 |
| Previous Close | 27.97 |
| Day's Range | 27.84 - 28.58 |
| 52-Week Range | 23.58 - 28.75 |
| Analyst | Buy |
| Price Target | 28 (-2.00%) |
| Dividends | $1.72 (6.15%) |
| Ex-Dividend Date | Jul 24, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, N...
Financial Performance
In 2025, Pfizer's revenue was 62.58B, a decrease of -1.65% compared to the previous year's 63.63B. Earnings were 7.77B, a decrease of -3.24%.
Financial StatementsAnalyst Forecast
According to 26 analyst ratings, the average rating for PFE stock is "Buy". The 12-month stock price forecast is 28, which is downside of 2% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $15.03B misses estimates by $0, with 2.60% YoY growth.
- EPS of 0.77 exceeds estimates by 0.09, with -1.28% YoY decline.
Analysts project revenue of ... Upgrade
